As Covid-19 cases rise once again across parts of Asia, particularly in Singapore and Hong Kong, two emerging subvariants — LF.7 and NB.1.8 — are fueling the recent surge. These subvariants, descendants of the highly contagious JN.1 variant and part of the Omicron family, possess mutations that allow them to partially evade immunity from previous infections and vaccinations. While their symptoms remain generally mild, their increased transmissibility and ability to bypass immune defenses pose ongoing challenges to public health efforts.
Enhanced Immune Escape and Vaccine Implications
Unlike earlier Covid variants such as Alpha, Delta, or the original Omicron subvariant BA.1, LF.7 and NB.1.8 have evolved mutations in their spike proteins, the viral component targeted by vaccines and antibodies. These changes enhance their ability to evade the immune system, increasing the chances of reinfections and breakthrough cases. The World Health Organization (WHO) has noted that despite this immune escape, updated vaccines, especially those targeting Omicron-related strains, continue to provide strong protection against severe illness and hospitalization. Booster doses remain a crucial tool in maintaining immunity as the virus evolves.
Rapid Spread and Mild Symptoms
LF.7 and NB.1.8 are more transmissible than their predecessors, which explains their dominance in recent outbreaks. In Singapore, these subvariants account for over two-thirds of sequenced cases, correlating with a 28% increase in infections in early May 2025. Hong Kong has also reported a sharp rise in positivity rates, nearly doubling in four weeks. Despite this rapid spread, the clinical symptoms mostly mirror those seen with other Omicron strains — mild fever, fatigue, sore throat, and cough. This mildness, however, complicates detection and containment efforts, especially since many cases go unnoticed due to the lack of severe illness.
The WHO currently classifies LF.7 and NB.1.8 as Variants Under Monitoring, highlighting the importance of ongoing surveillance as their full impact on transmission and vaccine efficacy remains under study. Their subtle spread, combined with partial vaccine resistance, underscores the need for vigilance as public health systems navigate this evolving phase of the pandemic.
